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Abstract
Background: Atherosclerosis is a complex disease with hundreds of genes influencing its progression. In addition, the
phenotype of the disease varies significantly depending on the arterial bed.
Methodology/Principal Findings: We characterized the genes generally involved in human advanced atherosclerotic (AHA
type V–VI) plaques in carotid and femoral arteries as well as aortas from 24 subjects of Tampere Vascular study and
compared the results to non-atherosclerotic internal thoracic arteries (n=6) using genome-wide expression array and QRT-
PCR. In addition we determined genes that were typical for each arterial plaque studied. To gain a comprehensive insight
into the pathologic processes in the plaques we also analyzed pathways and gene sets dysregulated in this disease using
gene set enrichment analysis (GSEA). According to the selection criteria used (.3.0 fold change and p-value ,0.05), 235
genes were up-regulated and 68 genes down-regulated in the carotid plaques, 242 genes up-regulated and 116 down-
regulated in the femoral plaques and 256 genes up-regulated and 49 genes down-regulated in the aortic plaques. Nine
genes were found to be specifically induced predominantly in aortic plaques, e.g., lactoferrin, and three genes in femoral
plaques, e.g., chondroadherin, whereas no gene was found to be specific for carotid plaques. In pathway analysis, a total of
28 pathways or gene sets were found to be significantly dysregulated in atherosclerotic plaques (false discovery rate [FDR]
,0.25).
Conclusions: This study describes comprehensively the gene expression changes that generally prevail in human
atherosclerotic plaques. In addition, site specific genes induced only in femoral or aortic plaques were found, reflecting that
atherosclerotic process has unique features in different vascular beds.
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Introduction
Atherosclerosis is a complex disease characterized by endothe-
lial cell dysfunction, smooth muscle cell proliferation and
migration, inflammation, lipid and matrix accumulation and
thrombus formation with hundreds of genes influencing its
progression. Susceptibility to atherosclerosis is in turn influenced
by complex gene-gene and gene-environment interactions making
atherosclerosis a challenging research subject.
Gene expression techniques, such as microarrays and represen-
tational difference analysis, are powerful tools that can be used to
discover the complexities underlying the development of athero-
sclerotic plaque. This method has previously been used to detect
differentially expressed genes in normal and diseased arteries [1,2],
disease progression [3], detecting differentially expressed genes
according to patient symptomatology [4] and discovering
pathways affected in coronary atherosclerosis [5]. When consid-
ering the large amount of genes influencing the development of
atherosclerosis focusing into pathway characterization provides a
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e33787comprehensive insight about the pathological mechanisms under-
lying atherosclerosis. On the other hand, single-gene approach
may be utilized when analyzing fundamental genes in complex
signalling systems.
Although atherosclerosis has a systemic nature, the susceptibility
to develop atherosclerotic lesions and the histological type of
atherosclerosis differs strikingly between different sites in human
vasculature. The type of atherosclerosis ranges from stable
calcified plaques and fibrotic plaques all the way to unstable
ulcerated plaques and the prevalence of these lesions varies
according to vascular bed region. For example, ulcerated plaques
in symptomatic carotid stenosis patients are common while fibrotic
and calcified lesions dominate in aortic and femoral areas raising
the question whether this dissimilarity could also be seen in the
gene expression profiles in different vascular regions.
We, therefore, screened the global gene expression profile of
advanced atherosclerotic plaques in carotid arteries, femoral
arteries and aortas and compared the results to non-atherosclerotic
left internal thoracic arteries (LITA) and identified most up- and
down-regulated genes in each arterial bed and searched for genes
that would be specific for one arterial region, and in addition,
characterized genes that were generally involved in disease. Using
gene set enrichment analysis (GSEA), we also analyzed pathways
(available in MSigDB database) that were generally affected in
atherosclerotic plaques.
Methods
Tampere Vascular Study (TVS) material
The atherosclerotic vascular sample series for GWEA consists of
atherosclerotic plaques from the following arterial sites: femoral
artery (n=4) carotid artery (n=9) and abdominal aorta (n=7) and
control samples from internal thoracic arteries (ITA) during
coronary artery bypass surgery (n=6) all together from a total of
26 patients participating in Tampere Vascular Study. All the
samples were handled and obtained in a standardized fashion
supervised by senior scientist in our laboratory. All the samples
from atherosclerotic arteries were obtained by endarterectomy
under loupe magnification obtaining a sample that consists of the
plaque with intima and the inner media. All these procedures were
performed by vascular surgeons under the surveillance of one of
the principal investigators (NO). ITA samples consisted of arterial
rings obtained during dissection and with all the arterial layers
including outer media and adventitia. All the patients had a
polyvascular disease (i.e. at least two major arterial beds affected
by atherosclerotic plaques as evidenced by 1) previous transient
ischemic attack and/or atherosclerotic plaques in the cerebral
vasculature or 2) coronary atherosclerosis as evidenced by previous
myocardial infarction or 3) angina pectoris and atherosclerotic
plaques in coronary angiography or 4) objectively verified
peripheral arterial disease by ankle-brachial pressure index ,0.9
or 5) previous arterial surgery due to atherosclerosis or 6)
angiographical demonstration of arterial plaques. Of these
patients, only two had polyvascular disease and all the rest had
monovascular disease limited to the coronary vasculature. The
sample population demographics are presented as Table S1. The
population had strong male predominace. The aortic group were
the youngest and had seldom dyslipidemia and diabetes. The
control group had more seldom hypertension and diabetes. The
cholesterol levels were highest in femoral and control group.
Smoking was frequent, especially in aortic group.
For the relative gene expression analysis, 24 atherosclerotic
tissue samples were used (2 from the original sample set could not
be recovered) and similarly, the six ITA vessels were used as
controls. The vascular samples were histologically classified
according to the American Heart Association classification
(AHA) [6]. The carotid and femoral artery samples were type V
or VI, aorta samples were type VI and all control vessels were
healthy. The study was approved by the Ethics Committee of
Tampere University Hospital (Permission number 99204). All the
patients gave written informed consent. The samples were taken
from patients subjected to open vascular surgical procedures at the
Division of Vascular Surgery, Tampere University Hospital. All
the patients gave informed consent.
RNA isolation and genome wide expression analysis
The fresh tissue samples were soaked in RNALater solution
(Ambion Inc., Austin, TX, USA) and isolated with Trizol reagent
(Invitrogen, Carlsbad, CA, USA) and the RNAEasy Kit (Qiagen,
Valencia, CA, USA). The concentration and quality of the RNA
was evaluated spectrophotometrically (BioPhotometer, Eppendorf,
Wesseling-Berzdorf, Germany). More than 23,000 known and
candidate genes were analyzed using Sentrix Human-8 Expression
BeadChips, according to manufacturer’s instructions. (Illumina,
San Diego, CA, USA). In brief, a 200 ng aliquot of total RNA
from each sample was amplified to cDNA using the Ambion’s
Illumina RNA Amplification kit according to the instructions
(Ambion, Inc., Austin, TX, USA). Each sample cRNA (1500 ng)
was hybridized to Illumina’s Sentrix Human-8 Expression
BeadChip arrays (Illumina). Hybridized biotinylated cRNA was
detected with 1 mg/ml Cyanine3-streptavidine (Amersham Bio-
sciences, Pistacataway, NJ, USA). BeadChips were scanned with
the Illumina BeadArray Reader. The method has been described
in more detail in our previous work [7].
Bioinformatics and statistical analyses
The data was archived using the minimum information about a
microarray experiment (MIAME 1.1. Draft 6). Raw intensity data
obtained from the IlluminaTM platform were normalized with R
language and environment for statistical computing and related
Bioconductor module [8]. Bioconductor module was also used to
conduct single-probe analysis including fold-change calculations
and filtering the probes. The statistical analysis was carried out
using the Limma package [9]. -Pathway analysis of the expression
data (all diseased vs. controls) was performed using the GSEA
implemented in GSEA java desktop application version 2.0 and
MsigDB (Molecular Signature Database) version 2.0. Statistical
analysis was performed using SPSS version 14.0. (SPSS Inc.,
Chicago, IL, USA). The non-parametric Mann-Whitney U-test
with post-hoc correction was used for comparison of mRNA
expression between atherosclerotic and control tissues and to find
differentially expressed genes. The results are presented as average
fold change. The averaging was done for each arterial bed. The
selection criteria were .3.0-fold change in gene expression and p-
value less than 0.05. The agreement between GWEA and TLDA
was evaluated by first classifying the results as down-regulated,
neutral or up-regulated. Then the number of samples correctly
classified into these categories was calculated and was found to be
.90%.
Quantitative RT-PCR
Quantitative gene expression analyses were performed with
TaqMan low density arrays (TLDAs) (Applied Biosystems, Foster
City, CA, USA) using gene specific TaqMan gene expression
assays. Total-RNA (500 ng) was transcribed to cDNA using the
High Capacity cDNA Kit (Applied Biosystems) according to
manufacturer’s instructions. After the cDNA synthesis, the LDA
cards were loaded with 8 ml undiluted cDNA, 42 mlH 20, and
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according to the manufacturer’s instructions. Samples were
analyzed as duplicates, and both cDNA synthesis and PCR
reactions were validated for inhibition of amplification in PCR
and cDNA synthesis. Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) was used as a housekeeping gene. The results were
analyzed using SDS 2.2 Software (Applied Biosystems).
Immunohistochemistry
All samples were first dyed with haematoxyclin (HE) and
classified according to Stary et al. [6]. Immunocytochemistry was
performed using the N-HistofineH Simple Stain MAX PO staining
method (Nichirei Biosciences Inc., Tokyo, Japan)) and paraffin-
embedded vascular samples without any counterstain. Lactotrans-
ferrin (LTF)- immunoreactivity(IR) was detected with a rabbit
polyclonal antibody (dil. 1:100, Lifespan Bioscience, Seattle, WA,
USA). Vascular cell types were identified with mouse anti-human
muscle actin (dil. 1:30, clone HHF35; DakoCytomation, Glostrup,
Denmark), mouse anti-human endothelial cell (dil. 1:70, CD31,
clone JC70A; DakoCytomation) and mouse anti-human CD68
(dil. 1:70, clone PG-M1, DakoCytomation) was used as marker of
monocytes and macrophages. Neutrophil granulocytes were
identified using mouse anti-human neutrophil elastase antibody
(dil. 1:500, DakoCytomation). T-lymphocytes were recognized
with mouse anti-CD3 antibody (dil. 1:150, eBioscience Inc., San
Diego, CA) and B-lymphocytes were labelled with mouse anti-
CD20 (dil. 1:1000, DakoCytomation. The sections were subjected
to microwave antigen retrieval treatment as described earlier [10]
except for elastase antibody. Endogenous peroxidase activity was
extinguished by treating the section with with 0.3% H2O2 for
30 min. Subsequently the sections were incubated overnight with
the primary antibodies followed with appropriate N-Histofine
staining reagent for 30 min. ImmPACT
TM (Vector Laboratories,
Burlingame, CA, USA) diaminobenzidine-solution with nickel-
intensification was used as the chromogen. All antibodies were
diluted in PBS containing 1% BSA and 0.3% of Triton X-100.
Controls included omitting the primary antibody or replacing it
with non-immune sera. No staining was seen in the controls. The
co-localization of LTF with different markers was studied in
adjacent 5 mm sections (mirror image sections). Sections were
stained as described above. Photographs were obtained using
Nikon FXA-100 microscope equipped with PCO Sensicam digital
camera (PCO, Kelheim, Germany).
Results
Overall gene expression changes observed in carotid,
femoral and aortic plaques
Several genes were found to have significantly altered
expression in advanced atherosclerotic carotid and femoral artery
plaques as well as in the aortas studied with GWEA. According to
the selection criteria used (.3.0 fold change and p-value ,0.05),
235 genes were up-regulated and 68 genes down-regulated in type
V–VI carotid plaques. For type V–VI femoral plaques, 242 genes
were up-regulated and 116 genes down-regulated. In type VI
aortic plaques, 256 genes were up-regulated and 49 genes down-
regulated (Table S2, S3, S4, S5, S6, S7). In order to identify
globally affected genes, we combined all gene expression results
and calculated average fold changes. Of these, 27 most up-
regulated and 16 down-regulated genes were verified with QRT-
PCR (TLDA) (Table 1 and 2). The concordance between GWEA
and TLDA was over 90%.
Among the most up-regulated genes verified with QRT-PCR in
atherosclerotic plaque (Table 1), we found genes already
previously connected to atherosclerosis, like matrix metalloprotei-
nases [11], apolipoproteins [12] and osteopontin [13], but we also
found new genes, not found to be involved in the pathogenesis of
atherosclerosis, namely interleukin 4 induced 1 (IL4I1), interferon,
gamma-inducible protein (IFI30), SLAM family member 8
(SLAMF8), and immunoglobulin J polypeptide (IGJ). Previously,
gene expression profiling of human atherosclerotic coronary
arteries did not reveal the involvement of these genes in the
pathogenesis on atherosclerosis [14,5].
We quantitated the 16 most generally down-regulated genes in
advanced atherosclerotic plaques using QRT-PCR. For most of
the genes on this list there are only few studies in the literature and
no information about their connection to atherosclerosis. The
significantly down-regulated genes in all the plaques studied are
shown in Table 2.
Site-specific gene expression alterations in different
arterial beds
According to GWEA data, we found nine genes that were
induced only in aortic plaques and three genes that were
specifically induced in femoral plaques of which expression was
verified with QRT-PCR. Genes induced predominantly in aortic
plaques differed considerably from the genes induced in femoral
plaques. Most of the genes induced in aortic plaques are involved
in immunological processes, especially involving B cells whereas
the genes induce in femoral plaques function mainly in extra-
cellular matrix modifications (Table 3). The genes that were
induced in carotid arteries, were also induced in aortic and
femoral plaques, thus no specific gene for carotid plaques was
found. To verify the predominant expression in only one arterial
bed region, we ascertained the protein localization of one of the
aortic plaque specific genes; LTF, a major immune system
modulator [15]. Using IHC, LTF protein was found predomi-
nantly in aortic plaques mainly in necrotic debris in intima and
inner media wherein localized to neutrophils, B and T
lymphocytes (Figures 1 and 2). In femoral and carotid arteries,
LTF was present only in sparse cells being mostly unoccupied by
LTF positive cells (Figures 3 and 4).
Altered pathways in advanced atherosclerotic lesions
In order to identify globally affected pathways in advanced
atherosclerosis, we performed gene set expression analyses (GSEA)
to illuminate dysregulated pathways. In the pathway analyses, 20
pathways appeared to be significantly up-regulated and 8
pathways down-regulated in advanced atherosclerotic plaques as
compared to non-atherosclerotic arteries according to the criteria
recommended by Subramanian et al. (FDR,0.25) [16] (Table
S8). Significantly up-regulated pathways involved apoptotic and
pro-inflammatory pathways as well as pathways involved in
complement or B cell activation and cell movement. The
significantly altered down-regulated pathways included fatty acid
metabolism and amino acid metabolism pathways, glutamate
receptor pathway, benzoate degradation pathway and pathway
including genes of hormonal functions. Interestingly, a pathway
including HOX genes related to hematopoiesis was significantly
down-regulated.
Despite intensive research on the role of T cells in atherogenesis,
this is the first time that all the major genes involved in T cell
differentiation are described from three major atherosclerotic
arterial beds. In order to verify the results of the pathway analysis,
we quantitated with QRT-PCR the expression of all genes
belonging to nkTPathway (Biocarta) (natural killer T-cells)
containing genes involved in T cell differentiation. The pathway
included a total of 29 genes of which 26 were significantly up-
New Genes in Atherosclerosis
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atherosclerotic arteries (Table 4). In general, the highest fold
changes were seen in aortas (for exact fold changes in different
vascular beds, see Table S9). Despite the classical T cell genes
already known to be activated, several other genes were also
significantly altered in plaques, e.g., chemokine receptors 3,4, and
7 (CCR3, CCR4, CCR7), interferon gamma receptor 1–2
(IFNGR1, IFNGR2), interleukin 12 receptor beta 1–2 (IL12RB1,
IL12RB2), interleukin 18 receptor 1 (IL18R1), interleukin 4
receptor (IL4R), and transforming growth factor beta 2 (TGFB2).
Discussion
The present scan of all known human genes in the
atherosclerotic plaques from carotid and femoral arteries as well
as from the aortas revealed novel genes involved generally in
atherosclerosis and specifically in different vascular regions. In
addition, we revealed pathways and gene sets that were
significantly dysregulated in advanced atherosclerotic plaques
and verified the expression of all genes in one of the most up-
regulated pathways that is involved in T cell differentiation.
Many of the genes found in this study have been linked to
atherosclerosis also in previous studies. Although, due to rapidly
evolved whole genome microarray technology, it is challenging to
directly compare the results with those of the previous studies
[2,1,5,3]. Furthermore, these studies have utilized samples at
different stage of atherosclerosis from organ donors and autopsies
[2,1,3] whereas pathway analysis has been done focusing only in
the coronary region in the heart transplantation patients [5].
New genes involved in advanced atherosclerosis
In addition to genes already linked to atherosclerosis, we also
found a new set of genes, not previously found in atherosclerotic
plaques, or even otherwise connected to the disease. IL4I1
(FC+35.2), is expressed by B-cells, [17,18] and in inflammatory
conditions by macrophages and dendritic cells [19]. Interferon,
gamma-inducible protein 30 (IFI30) (FC+23.2) demonstrated high
expression and it has not been previously identified in atheroscle-
rosis. Since both IL41I [19], and IFI30 [20,21] participate in the
down-regulation of Th1 mediated inflammation, a crucial element
in atherosclerosis [22,23], our results of high expression of IL41I
and IFI30 may reflect a negative feedback response to Th1
mediated inflammation in the atherosclerotic process. Our results
of the involvement of IFI30 and IFI30 in the regulation of Th1
cells opens new possibilities to modulate the immune reactions
responsible for atherogenic processes. It is also interesting to note
that even though some immunoglobulins, like IgG and IgM
[24,25], have already been linked to atherosclerosis, there is no
Table 1. The most up-regulated genes generally in atherosclerotic plaques analysed with TaqMan Low Density array.
Gene abbreviation Gene ID Average FC
MMP12 (matrix metallopeptidase 12) 4321 473.7 (p,0.0001)
MMP7 (matrix metallopeptidase 7) 4316 686.1 (p,0.0001)
SPP1 (secreted phosphoprotein 1) 6696 173.0 (p,0.0001)
APOC1 (apolipoprotein C–I) 341 154.8 (p,0.001)
MMP9 (matrix metallopeptidase 9) 4318 125.3 (p,0.001)
CCL18 (CC chemokine ligand 18) 6362 105.7 (p,0.001)
ACP5 (acid phosphatase 5) 54 57.7 (p,0.001)
APOE (apolipoprotein E) 348 52.9 (p,0.001)
IL4I1 (interleukin 4 induced 1) 259307 35.2 (p,0.001)
RGS1 (regulator of G-protein signaling 1) 5996 19.9 (p,0.001)
HMOX1 (heme oxygenase 1) 3162 20.5 (p,0.001)
IFI30 (interferon, gamma-inducible protein 30) 10437 23.2 (p,0.001)
SLAMF8 (SLAM family member 8) 56833 22.0 (p,0.001)
MGC29506 (hypothetical protein) 51237 19.2 (p=0.001)
THBS1 (thrombospondin 1) 7057 13.8 (p=0.000)
LYZ (lysozyme) 4069 10.8 (p,0.001)
IGJ (immunoglobulin J polypeptide) 3512 14.1 (p=0.001)
TYMP (thymidine phosphorylase) 1890 14.0 (p,0.001)
IL8 (interleukin 8) 3576 12.0 (p,0.001)
COL1A1 (collagen, type I, alpha 1) 1277 5.7 (p,0.001)
CAPG (capping protein) 822 7.4 (p,0.001)
ADFB (adipose differentiation-related protein) 123 6.4 (p,0.001)
LGALS3 (lectin, galactoside-binding, soluble, 3) 3958 1.8 (p=0.001)
CYBA (cytochrome b-245, alpha polypeptide) 1535 5.4 (p,0.001)
CFL1 (cofilin 1) 1072 1.3 (p=0.158)
ALDOA (aldolase A, fructose-bisphosphate) 226 1.2 (p,0.001)
HLA-DRP3 (major histocompatibility complex, class II, DR beta 3) 3125 28.8 (p=0.561)
The results are shown as an average fold change (FC) compared to control arteries.
doi:10.1371/journal.pone.0033787.t001
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[26], in atherosclerosis. Based on the NCBI Gene Expression
Omnibus database, IgJ has had elevated expression in some of the
samples in gene expression profiling of atherosclerotic coronary
arteries, but the results were controversial and did not support a
critical role in atherosclerosis [5]. In our study though, the
expression of IgJ in all three atherosclerotic arteries was obvious
with 14.1-fold up-regulation in plaques and with p-value of
p,0.001 warranting further studies.
We found several significantly up-regulated genes in plaques
without obvious implications in atherosclerosis. These genes
include e.g., CCL18 and RGS1, involved in lymphocyte
attraction, migration and function [27–29] and CAPG that is
suggested to modulate the protective effects of unidirectional shear
stress [30]. BLAME, a B cell costimulator and adhesion molecule
[31] that has previously found in human macrophages to be
induced in response to LDL [32] and now, found +22.0 –fold in
human advanced atherosclerotic plaques. Most of the significantly
down-regulated genes are new with regards to atherosclerosis. The
Table 2. The most generally down-regulated genes in atherosclerotic plaques analysed with TaqMan Low Density array.
Gene abbreviation Gene ID Average FC
ITLN1 (intelectin 1) 55600 2568.2 (p,0.001)
APOD (apolipoprotein D) 347 2103.9 (p,0.001)
DUSP26 (dual specificity phosphatase 26) 78986 221.3 (p,0.001)
CASQ2 (calsequestrin 2) 845 223.6 (p,0.001)
RGS5 (regulator of G-protein signaling 5) 8490 213.0 (p,0.001)
TCEAL2 (transcription elongation factor A (SII)-like 2) 140597 218.6 (p,0.001)
DES (desmin) 1674 215.8 (p=0.025)
CALD1 (caldesmon 1) 800 210.4 (p,0.001)
PPP1R3C (protein phosphatase 1) regulatory (inhibitor) subunit 3C) 5507 29.5 (p,0.001)
ADRA2C (adrenergic, alpha-2C-, receptor) 152 212.9 (p,0.001)
CSRP2 (cysteine and glycine-rich protein 2) 1466 28.6 (p,0.001)
SPEG (SPEG complex locus) 10290 24.2 (p,0.001)
CNN1 (calponin 1) 1264 24.3 (p,0.001)
C6orf117 (chromosome 6 open reading frame 117) 112609 28.7 (p,0.001)
LMOD1 (leiomodin 1) 25802 26.5 (p,0.001)
RAMP1 (receptor activity modifying protein 1) 10267 25.4 (p,0.001)
The results are shown as an average fold change (FC) compared to control arteries.
doi:10.1371/journal.pone.0033787.t002
Table 3. Genes that were induced only in aortic or femoral plaques compared to non-atherosclerotic internal thoracic arteries
analyzed with genome-wide expression array (GWEA).
Gene (ID) Gene ID Fold change Function
Aortic plaques
CHGA, chromogranin A 1113 5.8 Secretory granules formation, immunity against microbes [66], cancer
[67], hypertension and myocardial infarction [38,68]
CSF3, colony stimulating factor 3 1440 4.6 Survival/proliferation of neutrophils and macrophages [69],
arteriogenesis [70]
GAGE12I, G antigen 12I 26748 4.5 Antigen, anti-apoptotic factor [71,72]
C4orf7, choromosome 4 open reading frame 7 260436 4.3 B cell immunity, tumorigenesis [73]
GAGE6, G antigen 6 2578 4.0 Antigen, cancer [74]
LTF, lactotransferrin 4057 3.7 Immune modulator [15]
PRPH, peripherin 5630 3.6 Intermediate filament [75]
MS4A1, membrane-spanning 4-domains 931 3.5 B cell immunity [76,77], cancer [78]
Femoral plaques
C1QTNF3, C1q and tumor necrosis factor related protein 3 114899 3.4 Adipose tissue secreted protein, anti-inflammatory [79]
CHAD, chondroadherin 1101 3.9 Extracellular matrix structure modification [42,80]
PTN, pleiotrophin 5764 4.7 Cell differentiation [48], angiogenesis [47], cancer [81]
For all genes, the p-value was less than 0.05.
doi:10.1371/journal.pone.0033787.t003
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which was almost absent in atherosclerotic plaques compared to
non atherosclerotic internal thoraci‘c arteries. ITLN1 is a cell
surface phagocytotic receptor that recognizes specific bacterial cell
wall components [33] and the absence of ITLN1 has been
suggested to alter immune responses to infection and facilitate
inflammation [34]. Another significantly down-regulated gene was
the regulator of G-protein signalling 5 (RGS5). Recently, the
blockage of RGS5 has been suggested to provide an alternative
approach to treat hypertension but the biological impact of the
reduced expression of RGS5 in the plaques is not known.
Site-specific gene expression changes in vascular regions
studied
After carefully examining the GWEA data, we determined nine
genes specific for aortic plaques and three genes specific for
femoral plaques. We did not find any gene that would have been
Figure 1. Immunohistochemical staining of lactoferrin (LTF) in
advanced human atherosclerotic aorta. The picture was taken
with 1006magnitude.
doi:10.1371/journal.pone.0033787.g001
Figure 2. Co-localization of lactoferrin (LTF) with neutrophils
and T and B lymphocytes. Adjacent mirror image sections
demonstration the co-localization of LTF (A, C, E) with T-cell marker
CD3 (B), neutrophil granulocyte marker elastase (D) and B-cell marker
CD20 (F) in aortic plaques. Arrows point cells that are both LTF and
CD3-IR (A, B) or LTF and Elastane-IR (C, D). Most of the CD20-IR cells in a
lymph nodule (Ln) are also LTF-IR. Large number of LTF-IR cells in
surrounding tissue are not CD20-IR. The pictures were taken with 2006
magnitude.
doi:10.1371/journal.pone.0033787.g002
Figure 3. Immunohistochemical staining of lactoferrin (LTF) in
advanced human atherosclerotic femoral artery. The picture was
taken with 1006magnitude.
doi:10.1371/journal.pone.0033787.g003
Figure 4. Immunohistochemical staining of lactoferrin (LTF) in
advanced human atherosclerotic carotid artery. The picture was
taken with 1006magnitude.
doi:10.1371/journal.pone.0033787.g004
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that were specifically induced in aortic plaques are mostly involved
in immune reactions, especially in B cell immunity (Table 3).
We observed a significant up-regulation of LTF in aorta, located
in B- and T-cells and in neutrophils. LTF is an iron-binding
glycoprotein abundantly found in exocrine secretions of mammals
and released by mucosal epithelia and neutrophils during
inflammation [35] and binds to cells of the immune system [15].
The role of LTF as a negative regulator of inflammation, is a
key element in the host defence system and is capable of binding to
cells of the immune systems, e.g., cells of the monocyte lineage
[15]. LTF interacts with monocytes and macrophages and
modulates their function during inflammatory and infectious
processes, e.g., increasing cytotoxic activity, cytokine production
(Th1) and expression of surface molecules [36]. When considering
the fundamental role of macrophages in atherosclerosis, it is
interesting to speculate the reason whysucha powerful macrophage
regulator is induced predominantly in aortic plaques. Interestingly,
serum lactoferrin has been found to associate with fatal ischemic
heart disease in patients with diabetes [37]. Whether the LTF
expression induce specific immunological effects in aortic plaques
contributing to phenotype commonly observed in aortic plaques,
needs to be clarified in the future. At least, considering the wide
array of immunological functions, such speculation is justifiable.
Chromogranin A (CHGA) that acts as a prohormone giving rise
to several biologically active peptides [38], was another gene found
to be specific for aortic plaques. CHGA has been suggested to be a
fundamental regulator of blood pressure [38] and endothelial
barrier function [39] and interestingly, an independent predictor
of long-term mortality and heart failure of acute coronary
syndromes [40]. The biological role of CHGA in the pathogenesis
of atherosclerosis is not known but the ,6-fold up-regulation
specifically in aortic plaques may inspire future research.
The three genes induced specifically in femoral plaques differed
from the aortic plaque specific genes. Femoral plaques exist usually
in a stable phenotype with a placid fibrous cap and therefore it is
not surprising that chondroadherin, a cartilage matrix protein, was
,4-fold induced predominantly in femoral plaques. In addition of
being able to promote attachement of osteoblastic cells to solid
state substrates [41], CHAD interacts with integrin alpha2beta1
(a2b1) [42] and complement [43], both involved in atherogenic
processes [44–46].
Pleiotrophin (PTN) was ,5-fold up-regulated in femoral
plaques, has previously been found in atherosclerotic human
coronary arteries and suggested to participate in intraplaque
vascularization, inflammation [47] and monocyte/macrophage
differentiation into endothelial cell phenotype [48].
T cell differentiation pathway in atherosclerotic plaques
We found the pathway including genes involved in the
regulation of T cell chemokine pathway to be highly activated in
the advanced plaques. Taken the fundamental role of T cells in the
plaque formation and inflammation [49], we quantitated all the
genes belonging to this pathway in order to get a comprehensive
view about the extent how all the crucial T cell chemokines are
actually expressed in human plaques and even more, see the
trends of the pathway. Instead of focusing on well-known genes
involved in T cell activation, we discuss here genes with little or no
previous information at all regarding atherosclerosis.
IL12, secreted by macrophages dendritic cells and Th1 cells and
acting through IL12RB1/2 [50], is considered a proatherogenic
and proinflammatory cytokine contributing to chemotaxis and
migration [23,51]. IL12RB1 was 6-fold up-regulated in the
plaques and IL12RB2 3-fold, respectively. It is interesting to
speculate that the dissimilar expression of the two subunits of
IL12R may alter the consequences of IL12 binding and even may
have distinct effects of their own in the plaque immunological
reactions. Actually, IL12RB2 has already found to limit cancer
growth and thus proven to elicit an effect on its own [52].
IL2 and IL4 were the only interleukins on this pathway that were
generally down-regulated in plaques. Previously, pro-inflammatory
IL2 has been found to be associated with carotid artery intima-
media thickness [53]. Locally produced IL4 has earlier expected to
be protective towards an excessive pro-inflammatory response in
plaques [54,55] but there are also studies that suggest a pro-
atherogenic rolefor IL4 [56]. Considering the low expression of IL2
and IL4 mRNA in atherosclerotic plaques, the role of these
cytokines may not be significant in atherosclerosis. It is though
worth on mentioning that the receptor for IL4, IL4R, was actually
up-regulated in plaques. In addition of binding IL4, IL4R is also
capable of binding IL13, a cytokine with potential anti-inflamma-
toryactivity[57] raising the idea whether the role ofIL4R should be
investigated in more detail with regards inhibiting the pathologic
processes leading to atherosclerotic disease.
TGFB1–3 genes were all only mildly up-regulated in plaques
studied. A study by Mallat et al. with apoE-deifcient mice suggest a
major protective role for TGFB signaling in atherosclerosis. In this
study, inhibition of TGFB signaling was also found to induce an
unstable plaque phenotype [58]. The protective role seemed to
depend on the effects of TGFB on macrophages and T cells, major
players in atherosclerosis pathogenesis. As the expression of
TGFB1–3 was only mildly up-regulated in plaques, the induce-
ment of TGFB expression or signaling might offer new strategies
in preventing the plaque progression.
With the exception of CCR2 and CCR3, all the other CCRs in
this pathway were significantly up-regulated in plaques with fold
changes varying from 14.9 to 3.5 supporting the previously
suggested role of CCRs in this disease [59,60]. CCR3, a marker
for Th2 cells, showed significant down-regulation (fold change
24.5, p=0.012) only in carotid arteries suggesting that the Th2
response in carotid artery disease may differ from aortic and
femoral artery atherosclerosis.
Interferon gamma has been suggested to accelerate atheroscle-
rosis e.g. by activating macrophages and increasing their
production of nitric oxide and pro-inflammatory cytokines [61].
In our study, the expression of interferon gamma receptors 1 and 2
(IFNGR1, IFNGR2) was significantly up-regulated in all athero-
sclerotic arteries studied. Previously, IFNGR1 and 22 have been
found in carotid artery atheroma [62] but their role in the disease
is not known. Its is though interesting to note that IFNGR1 acts as
an major player in Th1 cell differentiation [63] and that IL4 has
been found to prevent the association of IFNGRs in the antigen
recognition [64]. In this study, the IL4 mRNA was low in
atherosclerotic plaques. Whether the low IL4 expression could
impact the function IFNGRs, remains to be evaluated in the
future. In addition, it remains to be seen in the future whether the
INFG mediated actions in atherosclerotic plaques could be
modulated through manipulation of its receptors.
Limitations of the study
In this study, non atherosclerotic internal thoracic arteries (ITA)
were used as control vessels in gene expression analysis. Even
though comparison of the gene expression between healthy and
diseased vessels from the same origin would have given more
accurate results, unfortunately we were not able to obtain any
healthy samples from the carotid or femoral arteries nor from the
aortas due to ethical issues. We still believe that ITA vessels
as controls provide valuable information for discovering the
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plaques. It must be emphasized that the differences in hydrostatic
pressure component in between the carotid and femoral territory,
vascular compliance, and the differences in flow velocity in aorta
compared with either carotid or femoral territory, result in huge
variation in endothelial shear stress and artery wall radial load
potentially modulating the gene expression. However, the present
data still provides valuable information about the mechanism that
hemodynamics may affect the development of atherosclerosis
although the significance of this factor cannot be separately
addressed in the present experimental setting. The gene expression
profile may also be affected by differences in the cell type
composition in different arterial beds which has not been
characterized in the present study. A laser micro-dissection with
appropriate mRNA quantitation method would provide cell
specific information about the expression of genes. This technique
has also previously been successfully applied to gene expression
studies with atherosclerotic arteries [2,65]. Another shortcoming is
that the control vessels contained outer media and adventitia not
present in atherosclerotic plaque samples. This approach may
enrich the cell types present only in the intima and inner media of
diseased vessels and thereby affecting gene expression results.
Since the macrophages are the dominating type of inflammatory
cells, the changes in macrophage related genes are also
pronounced. It must be emphasized that the different sample
groups were not adjusted for gender, age, lipid parameters or
medication. At the present, the study population consisted of
rather old (median age 70.0 years) subjects with a male
predominance, majority having hypertension and history of
smoking. This limits the generalization of the present results as
the present data is limited to a high risk populations with severe
symptoms and signs of atherosclerosis.
Conclusions
Atherosclerosis is a complex disease with numerous factors
influencing disease development and phenotype. We analyzed
advanced human atherosclerotic carotid and femoral artery
plaques as well as aortas and screened all genes that were
dysregulated in these arteries. In addition, we evaluated all the
pathways and gene sets that were differentially expressed in
Table 4. The expression of nkTPathway (natural killer T-cell) genes in atherosclerotic plaques from carotid arteries, aortas and
femoral arteries compared to non-atherosclerotic internal thoracic arteries analyzed with TaqMan low density array.
Gene abbreviation Gene ID Average FC
CSF2 (colony stimulating factor 2 (granulocyte-macrophage) 1437 qqq*
IL12B (interleukin 12B) 3593 qq*
CCR5 (chemokine (C-C motif) receptor 5) 1234 14.9 (p,0.001)
CXCR4 (chemokine (C-X-C motif) receptor 4) 7852 12.4 (p=0.001)
CCR1 (chemokine (C-C motif) receptor 1) 1230 10.7 (p,0.001)
CD4 (CD4 molecule) 920 10.2 (p,0.001)
CCL4 (chemokine (C-C motif) ligand 4) 6351 8.4 (p=0.001)
CCR7 (chemokine (C-C motif) receptor 7) 1236 8.1 (p=0.001)
CCL3 (chemokine (C-C motif) ligand 3) 6348 6.6 (p,0.001)
IL12RB1 (interleukin 12 receptor, beta 1) 3594 6.0 (p,0.001)
CD28 (CD28 molecule) 940 5.8 (p=0.001)
CXCR3 (chemokine (C-X-C motif) receptor 3) 2833 5.6 (p=0.001)
CCR4 (chemokine (C-C motif) receptor 4) 1233 3.5 (p=0.033)
CD40LG (CD40 ligand) 959 3.4 (p=0.008)
IFNG (interferon, gamma) 3458 3.1 (p=0.022)
IL12RB2 (interleukin 12 receptor, beta 2) 3595 3.0 (p=0.233)
IFNGR2 (interferon gamma receptor 2) 3460 2.9 (p,0.001)
IL12A (interleukin 12A) 3592 2.9 (p=0.009)
TGFB1 (transforming growth factor, beta 1) 7040 2.0 (p,0.001)
IL18R1 (interleukin 18 receptor 1) 8809 2.0 (p=0.007)
CCR2 (chemokine (C-C motif) receptor 2) 1231 1.9 (p=0.213)
IFNGR1 (interferon gamma receptor 1) 3459 1.7 (p=0.005)
IL4R (interleukin 4 receptor) 3566 1.4 (p=0.002)
TGFB2 (transforming growth factor, beta 2) 7042 1.4 (p=0.069)
IL5 (interleukin 5) 3567 1.5 (p=0.500)
IL4 (interleukin 4) 3565 21.2 (p=0.468)
IL2 (interleukin 2) 3558 22.1(p=0.836)
TGFB3 (transforming growth factor, beta 3) 7043 1.2 (p=0.350)
CCR3 (chemokine (C-C motif) receptor 3) 1232 21.7 (p=0.108)
Fold changes (FC) are calculated by comparing the median expression of genes in atherosclerotic arteries vs. controls. Notes.
*Highly expressed in atherosclerotic plaque.
doi:10.1371/journal.pone.0033787.t004
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expression changes prevailing in three major advanced arterial
beds and suggests several new, previously unknown genes to be
involved in the disease pathogenesis. As the three major arterial
beds; carotid, femoral, and aortic plaques were thoroughly studied
in this study, the results serve also as an excellent reference for
further studies in the future.
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